BiotechTube

citicoline + L-Alpha glycerylphosphorylcholine + cerebrolysin

Phase 3Completed
1 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Stroke

Conditions

Stroke

Trial Timeline

Jan 1, 2011 → Nov 1, 2011

NCT ID
NCT01388738

About citicoline + L-Alpha glycerylphosphorylcholine + cerebrolysin

citicoline + L-Alpha glycerylphosphorylcholine + cerebrolysin is a phase 3 stage product being developed by Brain Biotech for Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT01388738. Target conditions include Stroke.

What happened to similar drugs?

7 of 20 similar drugs in Stroke were approved

Approved (7) Terminated (6) Active (9)
🔄SPT-07A injectionSinopharmPhase 3
🔄warfarin tablets + Edoxaban tablets (high dose regimen-60mg) + Edoxaban tablets (low dose regimen-30mg) + placebo warfarin + placebo edoxabanDaiichi SankyoPhase 3
✅StatinShionogiApproved
✅AlteplaseKyowa KirinApproved
❌AbciximabEli LillyPhase 3
❌AbciximabEli LillyPhase 3
🔄Ticagrelor + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01388738Phase 3Completed

Competing Products

20 competing products in Stroke

See all competitors
ProductCompanyStageHype Score
SPT-07A injectionSinopharmPhase 3
36
Osmotic drugsSinopharmPre-clinical
33
Aspirin, ClopidogrelYuhanPre-clinical
26
DS-1040b + PlaceboDaiichi SankyoPhase 1/2
32
SUN13837 + placeboDaiichi SankyoPhase 2
27
DS-1040b + AspirinDaiichi SankyoPhase 1
29
piclozotan low dose + placebo + piclozotan high doseDaiichi SankyoPhase 2
27
DS1040b + PlaceboDaiichi SankyoPre-clinical
26
Pharmacological intensification based on olmesartanDaiichi SankyoPhase 2
35
warfarin tablets + Edoxaban tablets (high dose regimen-60mg) + Edoxaban tablets (low dose regimen-30mg) + placebo warfarin + placebo edoxabanDaiichi SankyoPhase 3
40
YM872 (zonampanel), t-PA (alteplase)Astellas PharmaPhase 2
35
ASP2246Astellas PharmaPhase 1/2
39
Neu2000KWL + Neu2000KWL + Neu2000KWL + PlacebosSun PharmaceuticalPhase 2
35
XY03-EA + XY03-EA PlaceboSun PharmaceuticalPhase 2
31
Redasemtide + PlaceboShionogiPhase 2
39
StatinShionogiApproved
43
AlteplaseKyowa KirinApproved
43
ONO-2506 + ONO-2506 + ONO-2506Ono PharmaceuticalPhase 2/3
38
AbciximabEli LillyPhase 3
32
AbciximabEli LillyPhase 3
32